ArticleRheumatology advances in practice2026
Real-world experience with Janus kinase inhibitors in rheumatoid and psoriatic arthritis: retention and discontinuation factors in a UK six-centre cohort.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate real-world use of Janus kinase inhibitors (JAKis) prescribed for RA and PsA. Methods: We conducted a retrospective review of all patients treated with baricitinib, filgotinib, tofacitinib and upadacitinib across six UK rheumatology centres from time of first use in routine care until November 2024. Standardised data were collected and retention was calculated using Kaplan-Meier analysis. Factors associated with JAKi discontinuation were analysed using multivariable Cox regression analyses. Results: A total of 985 patients [79.5% female, mean age 60 years, RA 849 (86.2%), PsA 136 (13.8%)] were reviewed. MTX and glucocorticoids (GCs) were co-prescribed in 43% and 33.6% of cases, respectively. Among GC users, dose reduction occurred in 18% and complete discontinuation in 61.8%. JAKis were prescribed as a first-line biologic DMARD in 7.5% and as a third-line or later in 78.8%. Median retention was 49 months (range 1-85; 95% CI 42.62, 55.37), with 52.8% remaining on treatment at censure, with no difference between RA and PsA populations. Retention on tofacitinib was significantly lower than baricitinib ( Conclusion: In a real-world setting, JAKi demonstrated high retention in RA and PsA, with a GC-sparing effect. Retention is lower for female sex, older age, tofacitinib
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.